Compare Biotech Stocks

Compare Biotech stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., AMGN, BIIB, BNTX, GILD) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$316.04 +0.3%	$297.24	$253.30 ▼ $346.85	$169.78B	0.53	2.55 million shs	9.99 million shs
BIIB Biogen	$140.90 -0.3%	$142.16	$128.51 ▼ $238.00	$20.62B	0.01	1.25 million shs	3.44 million shs
BNTX BioNTech	$95.38 -0.9%	$113.02	$76.53 ▼ $131.49	$22.89B	0.3	783,641 shs	787,017 shs
GILD Gilead Sciences	$107.08 +1.1%	$103.68	$62.07 ▼ $119.96	$133.35B	0.21	6.79 million shs	26.50 million shs
ILMN Illumina	$87.66 +3.4%	$108.20	$80.18 ▼ $156.66	$13.89B	1.17	2.10 million shs	3.82 million shs
MRNA Moderna	$32.66 +0.6%	$34.91	$29.25 ▼ $170.47	$12.60B	1.86	6.63 million shs	9.32 million shs
REGN Regeneron Pharmaceuticals	$658.48 -0.6%	$689.43	$642.00 ▼ $1,211.20	$71.99B	0.27	634,475 shs	1.87 million shs
VRTX Vertex Pharmaceuticals	$503.20 -1.4%	$467.89	$377.85 ▼ $519.88	$129.22B	0.41	1.22 million shs	2.28 million shs
IQV IQVIA	$185.85 +0.9%	$194.94	$179.28 ▼ $254.54	$32.77B	1.5	1.24 million shs	3.24 million shs
MTD Mettler-Toledo International	$1,198.09 -0.2%	$1,292.72	$1,142.91 ▼ $1,546.93	$24.97B	1.15	127,624 shs	210,236 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	+0.74%	+6.08%	+19.99%	+15.74%
BIIB Biogen	0.00%	+1.05%	+2.79%	-3.80%	-35.41%
BNTX BioNTech	0.00%	-4.11%	-19.09%	-15.65%	+5.98%
GILD Gilead Sciences	0.00%	-3.91%	-2.68%	+15.67%	+44.74%
ILMN Illumina	0.00%	+2.41%	-9.81%	-35.55%	-34.18%
MRNA Moderna	0.00%	-5.66%	-3.17%	-17.09%	-68.32%
REGN Regeneron Pharmaceuticals	0.00%	-1.26%	-5.39%	-6.18%	-31.90%
VRTX Vertex Pharmaceuticals	0.00%	-0.31%	+4.76%	+26.66%	+22.10%
IQV IQVIA	0.00%	+0.24%	-4.20%	-5.79%	-26.46%
MTD Mettler-Toledo International	0.00%	-2.70%	-8.00%	-2.65%	-8.04%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.0788 of 5 stars	2.2	2.0	3.3	3.9	3.1	2.5	0.6
BIIB Biogen	4.8297 of 5 stars	4.2	4.0	0.0	3.7	2.9	2.5	1.9
BNTX BioNTech	3.2239 of 5 stars	4.4	5.0	0.0	0.0	2.1	0.8	0.0
GILD Gilead Sciences	4.388 of 5 stars	2.4	3.0	1.7	4.1	2.9	2.5	1.9
ILMN Illumina	4.57 of 5 stars	4.2	3.0	0.0	4.2	2.5	1.7	1.3
MRNA Moderna	4.0919 of 5 stars	4.0	1.0	0.0	4.6	1.4	2.5	0.6
REGN Regeneron Pharmaceuticals	4.8126 of 5 stars	4.4	3.0	1.7	2.3	3.6	1.7	1.9
VRTX Vertex Pharmaceuticals	3.8231 of 5 stars	2.3	3.0	0.0	3.3	3.0	2.5	1.3
IQV IQVIA	4.7208 of 5 stars	4.4	3.0	0.0	4.6	3.0	1.7	1.3
MTD Mettler-Toledo International	3.765 of 5 stars	2.1	3.0	0.0	3.3	3.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.46	Hold	$314.04	-0.63% Downside
BIIB Biogen	2.43	Hold	$213.33	51.41% Upside
BNTX BioNTech	2.89	Moderate Buy	$143.73	50.69% Upside
GILD Gilead Sciences	2.72	Moderate Buy	$104.52	-2.39% Downside
ILMN Illumina	2.48	Hold	$140.90	60.73% Upside
MRNA Moderna	2.04	Hold	$59.00	80.65% Upside
REGN Regeneron Pharmaceuticals	2.76	Moderate Buy	$973.13	47.78% Upside
VRTX Vertex Pharmaceuticals	2.65	Moderate Buy	$506.70	0.69% Upside
IQV IQVIA	2.86	Moderate Buy	$249.05	34.01% Upside
MTD Mettler-Toledo International	2.11	Hold	$1,380.50	15.22% Upside

Current Analyst Ratings Breakdown

Latest Biotech Stocks Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	ILMN Illumina	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$247.00 ➝ $128.00
3/11/2025	ILMN Illumina	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00
3/11/2025	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44
3/11/2025	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $143.00
3/11/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$123.00 ➝ $130.00
3/11/2025	ILMN Illumina	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$156.00 ➝ $156.00
3/11/2025	ILMN Illumina	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$135.00 ➝ $115.00

(Data available from 3/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	5.08	$31.67 per share	9.98	$10.93 per share	28.91
BIIB Biogen	$9.68B	2.13	$23.14 per share	6.09	$114.71 per share	1.23
BNTX BioNTech	$2.75B	8.32	$4.10 per share	23.25	$92.17 per share	1.03
GILD Gilead Sciences	$28.75B	4.64	$8.46 per share	12.66	$15.44 per share	6.94
ILMN Illumina	$4.37B	3.18	$4.23 per share	20.72	$14.98 per share	5.85
MRNA Moderna	$3.20B	3.94	N/A	N/A	$28.33 per share	1.15
REGN Regeneron Pharmaceuticals	$14.20B	5.07	$43.24 per share	15.23	$268.50 per share	2.45
VRTX Vertex Pharmaceuticals	$11.02B	11.73	N/A	N/A	$63.90 per share	7.87
IQV IQVIA	$15.41B	2.13	$15.91 per share	11.68	$34.45 per share	5.39
MTD Mettler-Toledo International	$3.87B	6.45	$43.95 per share	27.26	($6.07) per share	-197.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$7.55	41.86	14.78	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
BIIB Biogen	$1.63B	$11.19	12.59	8.53	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/16/2025 (Estimated)
GILD Gilead Sciences	$480M	$0.37	289.41	13.20	0.71	1.67%	31.63%	10.38%	4/24/2025 (Estimated)
ILMN Illumina	-$1.22B	-$7.68	N/A	16.99	1.60	-27.95%	13.37%	5.49%	5/1/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$38.28	17.20	17.32	2.34	31.07%	16.32%	12.76%	5/1/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$2.20	N/A	28.74	2.11	-4.86%	-2.02%	-1.49%	5/5/2025 (Estimated)
IQV IQVIA	$1.37B	$7.50	24.78	15.23	1.99	8.91%	28.81%	7.02%	5/1/2025 (Estimated)
MTD Mettler-Toledo International	$863.14M	$40.53	29.56	25.20	3.30	22.29%	-591.54%	26.78%	5/8/2025 (Estimated)

Latest Biotech Stocks Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/13/2025	Q4 2024	MTD Mettler-Toledo International	$11.76	$12.41	+$0.65	$11.96	$1.01 billion	N/A
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A
2/10/2025	Q4 2024	VRTX Vertex Pharmaceuticals	$3.99	$3.54	-$0.45	$3.50	$2.78 billion	N/A
2/6/2025	Q4 2024	ILMN Illumina	$0.92	$0.86	-$0.06	$1.17	$1.08 billion	N/A
2/6/2025	Q4 2024	IQV IQVIA	$3.11	$2.90	-$0.21	$2.42	N/A	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A
2/4/2025	Q4 24	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.01%	+8.53%	126.09%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.60%	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.95%	+2.74%	854.05%	N/A
ILMN Illumina	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$0.88	0.13%	N/A	2.30%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IQV IQVIA	N/A	N/A	N/A	N/A	N/A
MTD Mettler-Toledo International	N/A	N/A	N/A	N/A	N/A

Latest Biotech Stocks Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
BIIB Biogen	0.27	1.35	0.90
BNTX BioNTech	0.01	7.33	7.21
GILD Gilead Sciences	1.24	1.50	1.20
ILMN Illumina	0.63	1.77	1.42
MRNA Moderna	N/A	3.67	3.62
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35
IQV IQVIA	2.12	0.84	0.84
MTD Mettler-Toledo International	N/A	1.02	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
BNTX BioNTech	15.52%
GILD Gilead Sciences	83.67%
ILMN Illumina	89.42%
MRNA Moderna	75.33%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%
IQV IQVIA	89.62%
MTD Mettler-Toledo International	95.07%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
BIIB Biogen	0.16%
BNTX BioNTech	19.20%
GILD Gilead Sciences	0.29%
ILMN Illumina	0.17%
MRNA Moderna	11.00%
REGN Regeneron Pharmaceuticals	7.48%
VRTX Vertex Pharmaceuticals	0.20%
IQV IQVIA	1.60%
MTD Mettler-Toledo International	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.21 million	533.50 million	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
BNTX BioNTech	6,133	239.97 million	193.71 million	Optionable
GILD Gilead Sciences	17,000	1.25 billion	1.24 billion	Optionable
ILMN Illumina	9,030	158.40 million	158.13 million	Optionable
MRNA Moderna	3,900	385.82 million	324.40 million	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.79 million	256.28 million	Optionable
IQV IQVIA	86,000	176.32 million	173.28 million	Optionable
MTD Mettler-Toledo International	18,000	20.84 million	20.51 million	Optionable

Biotech Stocks Headlines

Recent News About These Companies

Beddow Capital Management Inc. Has $1.38 Million Holdings in Mettler-Toledo International Inc. (NYSE:MTD)

March 23 at 6:00 AM | marketbeat.com

Lee Danner & Bass Inc. Invests $437,000 in Mettler-Toledo International Inc. (NYSE:MTD)

March 23 at 5:31 AM | marketbeat.com

Semanteon Capital Management LP Takes Position in Mettler-Toledo International Inc. (NYSE:MTD)

March 23 at 5:31 AM | marketbeat.com

iA Global Asset Management Inc. Has $1.47 Million Stock Position in Mettler-Toledo International Inc. (NYSE:MTD)

March 23 at 5:06 AM | marketbeat.com

Teacher Retirement System of Texas Acquires 1,662 Shares of Mettler-Toledo International Inc. (NYSE:MTD)

March 23 at 4:57 AM | marketbeat.com

Royal London Asset Management Ltd. Buys 1,045 Shares of Mettler-Toledo International Inc. (NYSE:MTD)

March 22 at 5:03 AM | marketbeat.com

Vinva Investment Management Ltd Reduces Stock Position in Mettler-Toledo International Inc. (NYSE:MTD)

March 22 at 5:02 AM | marketbeat.com

1,236 Shares in Mettler-Toledo International Inc. (NYSE:MTD) Bought by Generali Asset Management SPA SGR

March 22 at 4:36 AM | marketbeat.com

Thrivent Financial for Lutherans Reduces Stake in Mettler-Toledo International Inc. (NYSE:MTD)

March 22 at 4:35 AM | marketbeat.com

Raymond James Financial Inc. Takes Position in Mettler-Toledo International Inc. (NYSE:MTD)

March 22 at 3:18 AM | marketbeat.com

Mettler-Toledo International, Inc.

March 21 at 10:50 AM | money.usnews.com

Is Mettler-Toledo International Stock Underperforming the S&P 500?

March 21 at 10:50 AM | msn.com

Mettler-Toledo International Inc. (NYSE:MTD) Shares Acquired by Northwest & Ethical Investments L.P.

March 21 at 6:53 AM | marketbeat.com

Cibc World Markets Corp Buys 382 Shares of Mettler-Toledo International Inc. (NYSE:MTD)

March 21 at 4:32 AM | marketbeat.com

Here's Why Mettler-Toledo (MTD) is a Strong Growth Stock

March 18, 2025 | zacks.com

Choate Investment Advisors Reduces Stock Position in Mettler-Toledo International Inc. (NYSE:MTD)

March 17, 2025 | marketbeat.com

Corient Private Wealth LLC Sells 3,152 Shares of Mettler-Toledo International Inc. (NYSE:MTD)

March 17, 2025 | marketbeat.com

Skandinaviska Enskilda Banken AB publ Has $12.79 Million Stock Position in Mettler-Toledo International Inc. (NYSE:MTD)

March 16, 2025 | marketbeat.com

Vestcor Inc Sells 383 Shares of Mettler-Toledo International Inc. (NYSE:MTD)

March 16, 2025 | marketbeat.com

Swiss National Bank Reduces Position in Mettler-Toledo International Inc. (NYSE:MTD)

March 16, 2025 | marketbeat.com

Parnassus Investments LLC Sells 231 Shares of Mettler-Toledo International Inc. (NYSE:MTD)

March 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings
Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
By Jea Yu | February 22, 2025
View Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
By Jea Yu | February 27, 2025
View Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Biotech Stocks Company Descriptions

Amgen NASDAQ:AMGN

$316.04 +1.00 (+0.32%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$315.82 -0.22 (-0.07%)

As of 03/21/2025 07:58 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$140.90 -0.48 (-0.34%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$140.82 -0.09 (-0.06%)

As of 03/21/2025 07:58 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$95.38 -0.85 (-0.88%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$95.38 0.00 (-0.01%)

As of 03/21/2025 07:50 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Gilead Sciences NASDAQ:GILD

$107.08 +1.21 (+1.14%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$107.26 +0.19 (+0.17%)

As of 03/21/2025 07:56 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Illumina NASDAQ:ILMN

$87.66 +2.87 (+3.38%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$86.54 -1.12 (-1.28%)

As of 03/21/2025 07:59 PM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Moderna NASDAQ:MRNA

$32.66 +0.21 (+0.65%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$32.74 +0.08 (+0.26%)

As of 03/21/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$658.48 -4.14 (-0.62%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$662.95 +4.47 (+0.68%)

As of 03/21/2025 07:53 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$503.20 -6.98 (-1.37%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$506.06 +2.86 (+0.57%)

As of 03/21/2025 07:13 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

IQVIA NYSE:IQV

$185.85 +1.59 (+0.86%)

Closing price 03/21/2025 03:59 PM Eastern

Extended Trading

$183.18 -2.67 (-1.44%)

As of 03/21/2025 06:15 PM Eastern

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Mettler-Toledo International NYSE:MTD

$1,198.09 -2.29 (-0.19%)

Closing price 03/21/2025 03:59 PM Eastern

Extended Trading

$1,199.34 +1.24 (+0.10%)

As of 03/21/2025 04:38 PM Eastern

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Biotech Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest Biotech Stocks Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest Biotech Stocks Earnings

Compare Dividends

Latest Biotech Stocks Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

Biotech Stocks Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Biotech Stocks Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools